title: Lymphoma Microenvironment and Immunotherapy.
abstract: Understanding of the lymphoma tumor microenvironment is poised to expand in the era of next-generation sequencing studies of the tumor cells themselves. Successful therapies of the future will rely on deeper appreciation of the interactions between elements of the microenvironment. Although the phenotypic, cytogenetic, and molecular characterization of tumor cells in lymphomas has progressed faster than most other solid organ tumors, concrete advancements in understanding the lymphoma microenvironment have been fewer. This article explores the composition of the lymphoma tumor microenvironment; its role in immune surveillance, evasion, and drug resistance; and its potential role in the development of targeted therapies.
authors.affiliation: Department of Pathology & Laboratory Medicine, Yale University School of Medicine, 310 Cedar Street, PO Box 208023, New Haven, CT 06520-8023, USA. Electronic address: mina.xu@yale.edu.
authors.forename: Mina L
authors.initials: ML
authors.lastname: Xu
authors.affiliation: University of North Carolina School of Medicine, Department of Pathology and Laboratory Medicine, NC Cancer Hospital C3162-D, 101 Manning Drive, Chapel Hill, NC 27599, USA.
authors.forename: Yuri
authors.initials: Y
authors.lastname: Fedoriw
mesh_terms: D006801:Humans; D057131:Immune Evasion / Q000276:immunology; D007157:Immunologic Surveillance / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D059016:Tumor Microenvironment / Q000276:immunology*
keywords: Immune checkpoint; Immune surveillance; Immunomodulatory drugs; Tumor microenvironment; Tumor-associated macrophages